Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Top Page
Veracyte
(NASDAQ:VCYT)
Select Model
Select Model
Rating:71Outperform
Price Target:
$36.00
▲(9.82% Upside)
Action:UpgradedDate:03/17/26
The score is driven primarily by strengthened fundamentals (profitability and accelerating free cash flow with a low-leverage balance sheet) and supportive 2026 guidance with solid testing growth targets. Offsetting these positives, technical signals are bearish (below key moving averages with negative MACD), and valuation looks rich (P/E ~49.9) while 2026 margins are guided lower due to investment and PPC comparability headwinds.
Positive Factors
Cash generation & free cash flow
Sustained, high free cash flow and a sharp operating cash flow increase indicate durable internal funding capacity. Strong FCF supports continued R&D, product launches and M&A optionality without reliance on debt, improving long-term financial flexibility and capital allocation optionality.
High gross margins and restored profitability
Consistently strong gross margins and recent net margin inflection show structural unit economics, driven by the lower‑cost transcriptome platform. Durable margin advantage supports reinvestment while preserving operating leverage, enabling profitable scale as volumes grow over the next several years.
Product pipeline and platform execution
A clear launch roadmap plus a moved-to-scale transcriptome platform and digital assets create durable growth optionality. Planned 2026 launches paired with clinical evidence and a large digital pathology/transcriptome dataset support multi-year revenue diversification and improved clinical adoption curves.
Negative Factors
Reimbursement and commercialization timing risk
Key new-product revenue hinges on external reimbursement decisions and long clinical follow-up. MolDX reviews and multi-year evidence generation timelines can materially delay commercial uptake, compress near-term revenue contribution and force extended launch investment before sustained payer coverage.
Prior‑period collections (PPCs) and comparability noise
One-time PPCs boosted recent results and management excluded them from 2026 guidance, creating comparability headwinds. Reliance on episodic collections complicates trend assessment and could mask underlying organic growth softness unless test volumes and payer collections remain steady.
Moderate returns on a large equity base
A conservatively levered balance sheet provides stability but a large equity base has diluted return metrics. Moderate ROE implies the company must sustain above-trend growth or deploy capital efficiently to materially improve shareholder returns over time, or face constrained return expansion.
Veracyte (VCYT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.60B
Dividend YieldN/A
Average Volume (3M)898.59K
Price to Earnings (P/E)49.9
Beta (1Y)1.23
Revenue Growth16.41%
EPS GrowthN/A
CountryUS
Employees824
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.53
Shares Outstanding79,458,430
10 Day Avg. Volume907,681
30 Day Avg. Volume898,592
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue4.35
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda27.00
Forecast
1Y Price Target
$44.50Price Target Upside35.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.66
Revenue Forecast (FY)$575.76M
Veracyte Business Overview & Revenue Model
Company DescriptionVeracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
How the Company Makes MoneyVeracyte primarily makes money by providing diagnostic testing services and recognizing revenue when its tests are ordered by clinicians and performed on patient samples. The main revenue stream is test revenue: the company performs proprietary genomic tests (run through its laboratory operations) and bills payers (such as private insurers) and, where applicable, healthcare programs or patients depending on coverage and reimbursement. Revenue is therefore driven by (1) test volume growth (more physicians and health systems adopting the tests), (2) reimbursement coverage and payment rates achieved with payers, (3) the mix of tests performed (different tests can have different reimbursement levels), and (4) geographic expansion and channel penetration (e.g., broader access through health systems and ordering networks). Veracyte’s earnings are also influenced by evidence generation (clinical validation and utility studies that support guideline inclusion and payer coverage), and by commercial partnerships or integrations that expand physician awareness and sample flow; however, specific partnership details and their quantitative contribution to revenue are null.
Veracyte Key Performance Indicators (KPIs)
Any
Revenue By Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability, and indicating where the company is focusing its strategic efforts.
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability, and indicating where the company is focusing its strategic efforts.
Data provided by:
The Fly
The FlyVeracyte Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The earnings call conveyed a largely positive operational and financial story: robust revenue and volume growth, strong margins and cash generation, successful transition to a lower-cost transcriptome platform, substantial clinical evidence and data assets, and a clear product launch roadmap (TrueMRD and Prosigna) that sets up multi-year growth. Headwinds and risks were acknowledged—one-time prior-period collections (PPCs) amplified 2025 results and complicate comparability; planned investments and launch-related spending will temper margins in 2026; reimbursement timelines and near-term revenue contribution for new products (MRD, Prosigna, Percepta/NIGHTINGALE) remain uncertain. On balance, the highlights (top-line momentum, margins, cash, platform readiness, evidence generation, and pipeline) significantly outweigh the lowlights, which are mostly timing, one-time, or investment-related risks.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Q4 total revenue of $140.6M (management also cited ~$141M) representing 19% year-over-year growth; full-year 2025 revenue of $517M, up 16% year-over-year and at the high end of preliminary range.
Testing Revenue and Volume Expansion
Q4 testing revenue of $135.8M, up 21% YoY; total testing volume ~48,000 tests in Q4 (+16% YoY) and testing volume ~45,500 tests (+16% YoY). Afirma Q4 volume ~18,250 tests (+12% YoY); Decipher Q4 volume ~27,200 tests and marked the 15th consecutive quarter of >20% YoY volume growth.
Improving ASP and Gross Margin
Testing ASP of ~$2,984 in Q4, +4% YoY (normalized ASP $2,875, +1% YoY after PPC adjustment). Non-GAAP gross margin of 75.1% in Q4 (up 580 bps YoY); testing gross margin 76.1% (up 380 bps YoY), driven by operational efficiencies (v2 transcriptome) and PPCs.
Industry-Leading Profitability and Cash Generation
Adjusted EBITDA Q4 $42.3M (30.1% of revenue); full-year adjusted EBITDA margin 27.6% (exceeding 25% target more than a year ahead). GAAP net income Q4 $41.1M and $66.4M for FY2025. Generated $52.6M of cash from operations in Q4 and ended the quarter with $412.9M cash and cash equivalents; cash balance increased by >$120M over the year.
Platform Execution and Operational Efficiency
Completed full transition of Afirma to the more scalable, lower-cost v2 transcriptome (lower no-result rate: 2% improvement Q/Q), restructured Veracyte SAS, and fully moved Afirma volume to v2 enabling better throughput and cost structure.
Decipher Clinical Momentum and Adoption
Decipher ordering physicians increased 18% YoY in Q4; >300,000 prostate patients tested since launch with >100,000 tested in 2025 alone. Management cites ~33% market penetration for Decipher and forecasts sustained double-digit growth (Decipher revenue grew 27% in the quarter).
Evidence and Research Engine
Substantial publication and abstract activity: Decipher prostate >100 clinical utility/validity publications plus ~100 GRID research publications; numerous ASCO GU abstracts for prostate and bladder; Afirma GRID research continues to drive publications—supporting adoption and future product additions (new signatures).
Product Pipeline and Launches Scheduled for 2026
Two major product launches planned in 2026: TrueMRD (whole-genome MRD for muscle invasive bladder cancer) targeted H1 launch after MolDX technical assessment, and Prosigna LDT (PAM50) planned for U.S. launch over the summer on the new transcriptome workflow.
Digital Pathology and Data Assets
Implemented slide scanning as standard production workflow: scanned >210,000 slides from >150,000 patients with outcomes data, creating a large combined digital pathology + transcriptome dataset for future AI and biomarker development.
2026 Guidance Reiteration with Growth Targets
Reiterated 2026 revenue guidance of $570M–$582M (10%–13% YoY); testing revenue growth guidance of 14%–16% with Decipher ~20% growth and Afirma mid- to high-single-digit revenue growth; adjusted EBITDA margin targeted at ~25% for 2026.
Negative Updates
PPCs and One-Time Collection Effects
Prior period collections (PPCs) materially benefited 2025 results (~$10M recognized in 2025); management excluded PPCs from 2026 guidance and cited a headwind (~$10M) vs. prior-year, creating comparability noise and contributing to guidance conservatism.
Guidance Margins Moderation and Increased OpEx
Management is guiding adjusted EBITDA margin down to ~25% in 2026 from 27.6% in 2025, attributing the reduction to planned investments for launches and infrastructure. Non-GAAP operating expenses rose 12% YoY to $65.1M (R&D $19M, S&M $23.9M, G&A $22.3M).
Uncertain Near-Term Revenue Contribution from New Products
TrueMRD and Prosigna launches are expected to be strategic and evidence-driven with limited near-term revenue in 2026 (management emphasized seeding market, KOL engagement, and customer experience over immediate volume); launches not included in 2026 revenue guide.
Reimbursement and Timing Risks for MRD and NIGHTINGALE
TrueMRD reimbursement details (pricing) remain under MolDX review and are not finalized; NIGHTINGALE (Percepta nasal swab) completed enrollment but requires long follow-up/publication (1–2+ years) and extended reimbursement conversations—making commercialization timelines multi-year.
Biopharma Revenue Uncertainty and French Entity Shutdown
Biopharma revenue, which previously contributed via the French entity, is now uncertain with implied inclusion of <$1M in 2026 guidance; shutdown of the French entity reduced that revenue channel.
Quarterly Volatility and Seasonality
Q1 seasonality expected to reduce adjusted EBITDA margin sequentially (typical start-of-year comp/benefits/payroll tax and lower PPCs). Management noted quarter-to-quarter sample volatility (e.g., modest sequential Decipher volume shifts) and weather impacts on early-quarter volumes.
Reinvestment Trade-Offs Could Limit Near-Term Margin Upside
Management retains flexibility to invest more aggressively if they choose to 'go faster' on product launches; while high-ROI, these investments could further pressure margins versus the already-conservative ~25% target for 2026.
Company Guidance
Veracyte reiterated 2026 guidance of $570–$582 million in total revenue (10–13% year‑over‑year) with testing revenue growth of 14–16%; Afirma revenue is expected to grow in the mid‑ to high‑single digits and Decipher about 20%. The guide excludes revenue from planned 2026 launches (TrueMRD, Prosigna) and does not bake in prior‑period collections (there is a ~$10 million PPC headwind from 2025); upside to the high end could come from Afirma no‑result rate improvements, additional PPCs or Decipher volume/penetration outperformance. Management expects adjusted EBITDA margin of approximately 25% in 2026 (after achieving 27.6% in 2025 and 30.1% in Q4), with Q1 margin seasonally lower due to higher compensation/benefits/payroll taxes and lower PPCs; the company finished Q4 with $412.9 million cash and cash equivalents and generated $52.6 million of cash from operations in the quarter.Veracyte Financial Statement Overview
Summary
Strong financial inflection with sustained high gross margins (~65–70%), a decisive swing to profitability in 2024–2025 (2025 net margin ~12.8%), and accelerating cash generation (2025 operating cash flow ~$136M; free cash flow ~$127M). Balance sheet is conservatively levered (debt-to-equity ~0.03) with a sizable equity cushion, though returns on equity remain moderate and revenue growth decelerated in 2025.Income Statement
Revenue has scaled meaningfully over the period (from $117.5M in 2020 to $517.1M in 2025), with continued growth in 2025 (+4.4% vs. 2024) following a strong step-up in 2024. Profitability has inflected sharply: the business moved from sizable losses in 2020–2023 to solid profitability in 2024 and stronger results in 2025 (net margin improved to ~12.8% vs. ~5.4% in 2024). Gross margins are consistently strong (~65–70%), supporting operating leverage. Key watch-outs are the deceleration in top-line growth in 2025 and historical earnings volatility (loss-making years as recently as 2023).78
Positive
Balance Sheet
The balance sheet is conservatively levered with low debt relative to equity (debt-to-equity ~0.03 in 2025), and equity has grown over time (to ~$1.31B in 2025), providing a substantial capital cushion. Returns have improved alongside profitability, with return on equity rising to ~5.1% in 2025 from ~2.1% in 2024 and negative levels in 2020–2023. The main limitation is that returns, while improving, are still moderate for the size of the equity base.86
Very Positive
Cash Flow
Cash generation is a clear strength: operating cash flow rose to ~$136.3M in 2025 (from ~$75.1M in 2024), and free cash flow reached ~$126.6M with strong growth (+28.9% in 2025). Free cash flow is well-aligned with earnings (free cash flow running at ~93% of net income in 2025), indicating earnings quality. Earlier years show more variability (including negative free cash flow in 2021–2022), but the last two years reflect a more durable cash flow profile.82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 517.14M | 445.76M | 361.05M | 296.54M | 219.51M |
| Gross Profit | 360.05M | 298.14M | 248.15M | 194.95M | 145.11M |
| EBITDA | 89.62M | 49.20M | -49.41M | -6.98M | -60.18M |
| Net Income | 66.35M | 24.14M | -74.40M | -36.56M | -75.56M |
Balance Sheet | |||||
| Total Assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B |
| Cash, Cash Equivalents and Short-Term Investments | 412.89M | 289.44M | 216.45M | 178.85M | 177.16M |
| Total Debt | 39.65M | 50.74M | 12.63M | 14.72M | 18.85M |
| Total Liabilities | 96.44M | 124.07M | 70.80M | 81.22M | 91.31M |
| Stockholders Equity | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B |
Cash Flow | |||||
| Free Cash Flow | 126.63M | 63.81M | 34.26M | -1.01M | -37.00M |
| Operating Cash Flow | 136.31M | 75.10M | 44.22M | 7.54M | -31.62M |
| Investing Cash Flow | -9.21M | -56.27M | 15.11M | -29.39M | -739.21M |
| Financing Cash Flow | -4.22M | 4.90M | 2.84M | 3.49M | 596.32M |
Veracyte Technical Analysis
Negative
32.78
Price Trends
37.40
Negative
39.80
Negative
34.65
Negative
Market Momentum
-1.33
Negative
40.16
Neutral
60.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCYT, the sentiment is Negative. The current price of 32.78 is below the 20-day moving average (MA) of 34.41, below the 50-day MA of 37.40, and below the 200-day MA of 34.65, indicating a bearish trend. The MACD of -1.33 indicates Negative momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 60.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCYT.
Veracyte Risk Analysis
Veracyte disclosed 56 risk factors in its most recent earnings report. Veracyte reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Veracyte Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $2.60B | 49.86 | 5.33% | ― | 16.41% | ― | |
63 Neutral | $2.84B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $4.81B | -10.43 | -65.80% | ― | ― | -27.70% | |
56 Neutral | $5.23B | -12.63 | -179.00% | ― | ― | -40.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.56B | -67.82 | -79.16% | ― | 114.22% | 77.02% | |
43 Neutral | $2.26B | -13.21 | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
VCYT
Veracyte
31.84
0.02
0.06%
TVTX
Travere Therapeutics
26.84
6.31
30.74%
CELC
Celcuity
106.04
95.54
909.90%
IMVT
Immunovant
22.98
3.34
17.01%
ARQT
Arcutis Biotherapeutics
22.21
5.20
30.57%
IRON
Disc Medicine
58.17
5.93
11.35%
Veracyte Corporate Events
Business Operations and StrategyExecutive/Board Changes
Veracyte Appoints Kevin Haas as Chief Technology Leader
Positive
Mar 16, 2026
On March 16, 2026, Veracyte, Inc. announced it had appointed former Myriad Genetics executive Dr. Kevin Haas as Chief Development and Technology Officer, effective March 24, 2026, bringing extensive experience in technology, engineering and bioinformatics leadership to its executive team. The move signals Veracyte’s efforts to strengthen its technological and product-development capabilities as it competes in the precision diagnostics market.
Under an offer letter signed on March 13, 2026, Dr. Haas will receive a $500,000 base salary, be eligible for an annual cash bonus targeted at 55% of earnings, and be granted time-based and performance-based restricted stock units valued at $1.5 million each, subject to multi-year vesting and performance goals. Veracyte will also provide its standard executive indemnification, and confirmed there are no related-party or conflict-of-interest relationships tied to his appointment, underscoring standard governance practices.
The most recent analyst rating on (VCYT) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Veracyte stock, see the VCYT Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.